Monthly Archives: February 2013

FDA approves Stivarga for advanced GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.

By |2019-09-20T13:00:30-04:00February 25th, 2013|Clinical Trials, Drug Treatment, News, Stivarga|

The LRG Pushes for New Ways to Research Rare Disease

Communication is a two-way street, but unfortunately that is not always the case when finding ways to research rare disease. Sharing of data by researchers does not happen as easily, or as often as you [...]

By |2019-09-20T13:01:02-04:00February 21st, 2013|Clinical Trials, News, Research|

Antibody Slows GIST Growth According to Stanford University Study

A recent study at Stanford University School of Medicine shows that an antibody slows GIST growth. The study shows that the antibody binds itself to the surface of a GIST Tumor and causes the growth of cancer cells to slow in the mice they tested.

By |2019-09-20T13:03:22-04:00February 5th, 2013|Clinical Trials, Gleevec, News, Research|
Go to Top